Use of at least one strain of Lactobacillus probiotic bacteria selected from the group consisting of Lactobacillus plantarum 299, DSM 6595, Lactobacillus plantarum 299v, DSM 9843, Lactobacillus plantarum HEAL 9, DSM 15312, Lactobacillus plantarum HEAL 19, DSM 153 plantarus Lactobacum Lactobacum Lactobacillus HEAL 99, DSM 15316, Lactobacillus paracasei 8700: 2, DSM 13434 and Lactobacillus paracasei 02A, DSM 13432, for the manufacture of a pharmaceutical composition for the treatment and / or prevention of a viral infection selected from the group consisting of cold virus common, rhinovirus, adenovirus, para-influenza virus, respiratory syncytial virus, enterovirus and coronavirus.Uso de al menos una cepa de bacterias probióticas de Lactobacillus seleccionada entre el grupo que consiste en Lactobacillus plantarum 299, DSM 6595, Lactobacillus plantarum 299v, DSM 9843, Lactobacillus plantarum HEAL 9, DSM 15312, Lactobacillus plantarum HEAL 19, DSM 15313, Lactobacillus plantarum HEAL 99, DSM 15316, Lactobacillus paracasei 8700:2, DSM 13434 y Lactobacillus paracasei 02A, DSM 13432, para la fabricación de una composición farmacéutica para el tratamiento y/o prevención de una infección vírica seleccionada entre el grupo que consiste en virus del resfriado común, rinovirus, adenovirus, virus paragripal, virus respiratorio sincitial, enterovirus y coronavirus.
